bluebird bio (BLUE)
(Delayed Data from NSDQ)
$0.51 USD
+0.01 (2.28%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $0.51 0.00 (0.79%) 7:10 PM ET
2-Buy of 5 2
D Value B Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.51 USD
+0.01 (2.28%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $0.51 0.00 (0.79%) 7:10 PM ET
2-Buy of 5 2
D Value B Growth A Momentum C VGM
Zacks News
bluebird (BLUE) Undertakes Restructuring Moves to Curb Cash Burn
by Zacks Equity Research
bluebird (BLUE) intends to reduce the existing workforce by nearly 30% to reduce 2022 operating expenses by 35-40%. This is likely to generate cost savings of $160 million over two years.
Precigen (PGEN) Up on FDA Fast Track Tag for CAR-T Candidate
by Zacks Equity Research
Precigen (PGEN) is developing CAR T therapy candidate, PRGN-3006 UltraCAR-T, for treating acute myeloid leukemia in a phase I study. The FDA grants Fast Track designation.
bluebird (BLUE) Posts Q4 Loss, Hit by Regulatory Pipeline Woes
by Zacks Equity Research
bluebird (BLUE) reports in-line fourth-quarter 2021 earnings but misses on revenues. The FDA placing clinical holds on BLUE's pipeline candidates does not augur well for the stock.
Bluebird Bio (BLUE) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Bluebird (BLUE) delivered earnings and revenue surprises of 0% and 79.84%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Apellis Pharmaceuticals, Inc. (APLS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Apellis Pharmaceuticals, Inc. (APLS) delivered earnings and revenue surprises of -21.97% and 607.46%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Bristol Myers' (BMY) Breyanzi sBLA Gets FDA's Priority Review
by Zacks Equity Research
The FDA accepts Bristol Myers' (BMY) sBLA for Breyanzi under a priority review as a second-line treatment for relapsed/refractory large B-cell lymphoma. A decision is due on Jun 24, 2022.
Bluebird Bio (BLUE) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Anthem's (ANTM) Q4 Earnings Beat Estimates, Improve Y/Y
by Zacks Equity Research
Anthem's (ANTM) Q4 results reflect better revenues and a solid contribution from its Government Business and IngenioRx businesses, partly offset by escalating expenses.
Is a Beat in Store for HCA Healthcare's (HCA) Q4 Earnings?
by Zacks Equity Research
HCA Healthcare's (HCA) fourth-quarter earnings are likely to have gained from rising admissions and higher revenues.
Anthem (ANTM) Gears Up for Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Anthem's (ANTM) fourth-quarter results are likely to reflect gains from increased premiums and strong membership growth across its Medicare and Medicaid businesses, partly offset by rising expenses.
Biotech Stock Roundup: ZGNX's Acquisition News, REGN, BLUE's Updates & More
by Zacks Equity Research
Regulatory and other pipeline updates from Zogenix (ZGNX) and Regeneron (REGN) are among a few key highlights from the biotech sector during the past week.
bluebird (BLUE) Gene Therapies BLA Decision Delayed, Stock Down
by Zacks Equity Research
The FDA delays decisions dates on bluebird bio's (BLUE) regulatory submissions for beti-cel in thalassemia and eli-cel in cerebral adrenoleukodystrophy by three months.
bluebird's (BLUE) BLA for CALD Therapy Gets Priority Review
by Zacks Equity Research
bluebird's (BLUE) filing for eli-cel, a gene-therapy to treat cerebral adrenoleukodystrophy, gets priority review from the FDA.
Bluebird (BLUE) Loses 20.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Bluebird (BLUE) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
bluebird (BLUE) Filing for Thalassemia Therapy Gets Priority Review
by Zacks Equity Research
bluebird (BLUE) application seeking approval for beti-cel for thalassemia gets priority review in the United States.
Novo Nordisk (NVO) Gets Positive CHMP Opinion for Wegovy
by Zacks Equity Research
The CHMP gives a positive opinion on, and recommends approval to Novo Nordisk's (NVO) Wegovy for chronic weight management in adults with obesity.
bluebird (BLUE) Stock Down 19% on Q3 Earnings & Revenue Miss
by Zacks Equity Research
bluebird (BLUE) reports wider-than-expected loss for third-quarter 2021. It also misses revenue estimates. Shares decline 19% following the announcement.
Bluebird Bio (BLUE) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Bluebird (BLUE) delivered earnings and revenue surprises of -7.72% and -59.37%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Bluebird Bio (BLUE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bristol-Myers (BMY) Beats on Q3 Earnings & Sales, Tweaks View
by Zacks Equity Research
Bristol-Myers (BMY) beats on earnings and sales in the third quarter on the back of Revlimid, Eliquis, and Opdivo.
What is in Store for Bristol-Myers (BMY) in Q3 Earnings?
by Zacks Equity Research
Bristol-Myers' (BMY) Q3 earnings might have gained from strong demand for its multiple myeloma drug, Revlimid. Operating expenses might have jumped due to costs associated with the broader portfolio.
bluebird (BLUE) Gives Details on Oncology Business Spinoff
by Zacks Equity Research
bluebird (BLUE) provides information on stock distribution ratio and cash allocation for the planned spin-off of the oncology business.
Allogene (ALLO) Falls on FDA Clinical Hold on CAR-T Studies
by Zacks Equity Research
The FDA places Allogene's (ALLO) clinical studies evaluating AlloCAR T therapy candidates on hold, following chromosomal abnormality observed in an early-stage study patient receiving ALLO-501A.
bluebird (BLUE) Submits BLA for Gene-Therapy to Treat Thalassemia
by Zacks Equity Research
bluebird (BLUE) files BLA with the FDA for its gene therapy, betibeglogene autotemcel (beti-cel), in patients with transfusion-dependent ¿¿-thalassemia.
Why Is Bluebird (BLUE) Down 13.3% Since Last Earnings Report?
by Zacks Equity Research
Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.